Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2011

Open Access 01-12-2011 | Research article

ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma

Authors: Arindam Banerjee, Zheng-Sheng Wu, PengXu Qian, Jian Kang, Vijay Pandey, Dong-Xu Liu, Tao Zhu, Peter E Lobie

Published in: Breast Cancer Research | Issue 6/2011

Login to get access

Abstract

Introduction

ARTEMIN (ARTN) is an estrogen regulated growth factor, the expression of which promotes resistance to antiestrogen therapies and predicts poorer survival outcome of patients with estrogen receptor (ER) positive mammary carcinoma (ER+MC) treated with tamoxifen. ARTN is also expressed in ER negative mammary carcinoma (ER-MC). Herein, we determined the role of ARTN in ER-MC and defined the mechanism of action producing poor patient prognosis.

Methods

We modulated the expression of ARTN in two ER- (mesenchymal/claudin-low) mammary carcinoma cell lines (BT549 and MDA-MB-231) by forced expression or small interfering RNA (siRNA) mediated depletion. The effects of modulation of ARTN expression were examined by various in vitro measures of oncogenicity, including the expression of TWIST1 messenger RNA (mRNA) and protein. In vitro results were correlated to xenograft studies in immunodeficient mice. Co-expression of ARTN and TWIST1 and their association to poor survival outcome were examined in a cohort of patients with ER-MC. Pathway analysis was performed by pharmacological inhibition of phosphorylation of AKT (pAKT-Ser 473) or modulation of TWIST1 expression.

Results

ARTN expression resulted in ER-MC cells with enhanced mesenchymal characteristics, including increased invasion and a gene expression profile consistent with enhanced mesenchymal phenotype. ARTN stimulated ER-MC cell anchorage independent and 3D matrigel growth, endothelial cell adhesion and transmigration of ER-MC cells through an endothelial cell barrier. Forced expression of ARTN produced a larger, locally invasive tumour mass with tumour emboli that produced distant metastasis. ARTN regulated TWIST1 expression in ER-MC cells and ARTN expression was significantly correlated to TWIST1 expression in a panel of mammary carcinoma cell lines and in a cohort of patients with ER-MC. Low expression of both ARTN and TWIST1 predicted 100% relapse free and overall survival in patients with ER-MC, whereas high expression of both ARTN and TWIST1 was associated with a poor survival outcome. ARTN stimulated an increase in TWIST1 expression via increased AKT activity. siRNA mediated depletion of TWIST1 abrogated ARTN stimulated cellular behaviour associated with metastasis, and forced expression of TWIST1 abrogated the functional effects of ARTN depletion.

Conclusions

ARTN and TWIST1 synergize to produce a worse outcome in ER-MC and combined inhibition of ARTN and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) may therefore provide a novel therapeutic strategy in this subtype of mammary carcinoma.
Appendix
Available only for authorised users
Literature
1.
2.
Putti TC, El-Rehim DMA, Rakha EA, Paish CE, Lee AHS, Pinder SE, Ellis IO: Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2004, 18: 26-35.CrossRef
3.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
4.
Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research. 2010, 12: R68-10.1186/bcr2635.CrossRefPubMedPubMedCentral
5.
Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA: Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA. 2010, 107: 15449-15454. 10.1073/pnas.1004900107.CrossRefPubMedPubMedCentral
6.
Airaksinen MS, Saarma M: The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002, 3: 383-394. 10.1038/nrn812.CrossRefPubMed
7.
Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE: Artemin is oncogenic for human mammary carcinoma cells. Oncogene. 2009, 28: 2034-2045. 10.1038/onc.2009.66.CrossRefPubMed
8.
Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene. 2010, 29: 3228-3240. 10.1038/onc.2010.71.CrossRefPubMed
9.
Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin Z, Wu ZS, Liu DX, Zhu T, Lobie PE: Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology. 2010, 151: 909-920. 10.1210/en.2009-0979.CrossRefPubMed
10.
Tang J-Z, Kong X-J, Kang J, Fielder GC, Steiner M, Perry JK, Wu Z-S, Yin Z, Zhu T, Liu D-X, Lobie PE: Artemin-stimulated progression of human non small cell lung carcinoma is mediated by BCL2. Molecular Cancer Therapeutics. 2010, 9: 1697-1708. 10.1158/1535-7163.MCT-09-1077.CrossRefPubMed
11.
Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Buchler MW, Friess H: The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg. 2006, 244: 274-281. 10.1097/01.sla.0000217642.68697.55.CrossRefPubMedPubMedCentral
12.
Lee YM, Park T, Schulz RA, Kim Y: Twist-mediated activation of the NK-4 homeobox gene in the visceral mesoderm of Drosophila requires two distinct clusters of E-box regulatory elements. J Biol Chem. 1997, 272: 17531-17541. 10.1074/jbc.272.28.17531.CrossRefPubMed
13.
Yin Z, Xu XL, Frasch M: Regulation of the twist target gene tinman by modular cis-regulatory elements during early mesoderm development. Development. 1997, 124: 4971-4982.PubMed
14.
Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A: Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008, 14: 79-89. 10.1016/j.ccr.2008.06.005.CrossRefPubMed
15.
16.
Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A: TWISTing an embryonic transcription factor into an oncoprotein. Oncogene. 2010, 29: 3173-3184. 10.1038/onc.2010.92.CrossRefPubMed
17.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004, 117: 927-939. 10.1016/j.cell.2004.06.006.CrossRefPubMed
18.
Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L, Xu J: The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 2011, 21: 275-289. 10.1038/cr.2010.118.CrossRefPubMed
19.
Zhang Y, Su H, Rahimi M, Tochihara R, Tang C: EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer. 2009, 125: 2021-2028. 10.1002/ijc.24540.CrossRefPubMedPubMedCentral
20.
Clarke R, Brunner N: Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor driven phenotypes?. Trends Endocrinol Metab. 1996, 7: 291-301. 10.1016/S1043-2760(96)00127-0.CrossRefPubMed
21.
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102: 13550-13555. 10.1073/pnas.0506230102.CrossRefPubMedPubMedCentral
22.
Pandey V, Perry JK, Mohankumar KM, Kong X-J, Liu S-M, Wu Z-S, Mitchell MD, Zhu T, Lobie PE: Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology. 2008, 149: 3909-3919. 10.1210/en.2008-0286.CrossRefPubMedPubMedCentral
23.
Tang J-Z, Zuo Z-H, Kong X-J, Steiner M, Yin Z, Perry JK, Zhu T, Liu D-X, Lobie PE: Signal Transducer and Activator of Transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology. 2010, 151: 43-55. 10.1210/en.2009-0651.CrossRefPubMed
24.
Park JS, Kim KM, Kim MH, Chang HJ, Baek MK, Kim SM, Jung YD: Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 Expression. Anticancer Research. 2009, 29: 355-362.PubMed
25.
Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J: Genes that mediate breast cancer metastasis to the brain. Nature. 2009, 459: 1005-1009. 10.1038/nature08021.CrossRefPubMedPubMedCentral
26.
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature. 2005, 436: 518-524. 10.1038/nature03799.CrossRefPubMedPubMedCentral
27.
Hu J, Verkman AS: Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 2006, 20: 1892-1894. 10.1096/fj.06-5930fje.CrossRefPubMed
28.
Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-454. 10.1038/nrc822.CrossRefPubMed
29.
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009, 15: 2657-2665. 10.1158/1078-0432.CCR-08-2372.CrossRefPubMed
30.
Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SAW: Metastasis-associated protein 2 is a repressor of estrogen receptor {alpha} whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol. 2006, 20: 2020-2035. 10.1210/me.2005-0063.CrossRefPubMedPubMedCentral
31.
Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA: Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Research. 2007, 67: 10296-10303. 10.1158/0008-5472.CAN-07-2173.CrossRefPubMed
32.
Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X: TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene. 2009, 28: 1960-1970. 10.1038/onc.2009.61.CrossRefPubMed
33.
Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RHA, Shvarts A, Suijkerbuijk KPM, van Laar T, van der Wall E, Raman V, van Diest PJ, Tijsterman M, Vooijs M: The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2[alpha]. Oncogene. 2007, 27: 1501-1510.CrossRefPubMed
34.
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang L-H: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Research. 2007, 67: 1979-1987. 10.1158/0008-5472.CAN-06-1479.CrossRefPubMed
35.
Correll PH, Morrison AC, Lutz MA: Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol. 2004, 75: 731-737.CrossRefPubMed
36.
Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X: Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochemical and Biophysical Research Communications. 2007, 358: 925-930. 10.1016/j.bbrc.2007.05.023.CrossRefPubMed
37.
Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 2005, 207: 139-146. 10.1002/path.1829.CrossRefPubMed
38.
Chen J-Q, Russo J: ER[alpha]-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2009, 1796: 162-175. 10.1016/j.bbcan.2009.06.003.CrossRef
39.
Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA: Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 1993, 4: 193-201.PubMed
40.
Dickson RB, McManaway ME, Lippman ME: Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science. 1986, 232: 1540-1543. 10.1126/science.3715461.CrossRefPubMed
41.
Miyagawa S, Katsu Y, Watanabe H, Iguchi T: Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol. Oncogene. 2004, 23: 340-349. 10.1038/sj.onc.1207207.CrossRefPubMed
42.
Obrero M, Yu DV, Shapiro DJ: Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem. 2002, 277: 45695-45703. 10.1074/jbc.M208092200.CrossRefPubMed
43.
Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, Wong YC: Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene. 2004, 23: 474-482. 10.1038/sj.onc.1207128.CrossRefPubMed
44.
Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J: Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis. 2010, 31: 1376-1380. 10.1093/carcin/bgq120.CrossRefPubMed
45.
Zhao M, Mueller B, DiScipio R, Schraufstatter I: Akt plays an important role in breast cancer cell chemotaxis to CXCL12. Breast Cancer Research and Treatment. 2008, 110: 211-222. 10.1007/s10549-007-9712-7.CrossRefPubMed
46.
Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F: Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer. 2007, 96: 314-320. 10.1038/sj.bjc.6603533.CrossRefPubMedPubMedCentral
47.
Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, Nomura S, Kikkawa F: Twist expression in patients with cervical cancer is associated with poor disease outcome. Annals of Oncology. 2008, 19: 81-85. 10.1093/annonc/mdn316.CrossRefPubMed
48.
Xie F, Li K, Ouyang X: Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis. 2009, 26: 1025-1032. 10.1007/s10585-009-9292-5.CrossRefPubMed
49.
Vesuna F, Lisok A, Kimble B, Raman V: Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia. 2009, 11: 1318-1328.CrossRefPubMedPubMedCentral
50.
Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69: 1302-1313. 10.1158/0008-5472.CAN-08-2741.CrossRefPubMedPubMedCentral
51.
Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, Hogendoorn PC: Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer. 1999, 26: 237-246. 10.1002/(SICI)1098-2264(199911)26:3<237::AID-GCC8>3.0.CO;2-L.CrossRefPubMed
52.
Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, van de Vijver MJ: Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys. 1999, 45: 73-83. 10.1016/S0360-3016(99)00158-3.CrossRefPubMed
53.
Parl FF, Schmidt BP, Dupont WD, Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer. 1984, 54: 2237-2242. 10.1002/1097-0142(19841115)54:10<2237::AID-CNCR2820541029>3.0.CO;2-V.CrossRefPubMed
Metadata
Title
ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma
Authors
Arindam Banerjee
Zheng-Sheng Wu
PengXu Qian
Jian Kang
Vijay Pandey
Dong-Xu Liu
Tao Zhu
Peter E Lobie
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3054

Other articles of this Issue 6/2011

Breast Cancer Research 6/2011 Go to the issue

Viewpoint

New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours

Research article

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

Research article

Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

Review

Epigenetics in breast cancer: what's new?

Research article

Variants on the promoter region of PTEN affect breast cancer progression and patient survival

Research article

Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits